Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 12/20 | 0.52 |
| ▸ | ERBB2 | P04626 | 9/20 | 0.51 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.44 |
| ▸ | GFPT1 | Q06210 | 1/20 | 0.42 |
| ▸ | APAF1 | O14727 | 1/20 | 0.41 |
| ▸ | NSD2 | O96028 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.41 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.41 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.40 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.40 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5745140 | 0.83 | GFPT1 (0.48) | EGFRERBB2GFPT1APAF1NSD2 | |
| SCHEMBL5744477 | 0.83 | CASP3 (0.42) | EGFRERBB2GFPT1APAF1NSD2 | |
| SCHEMBL5744897 | 0.82 | GFPT1 (0.51) | EGFRERBB2MAP2K1GFPT1APAF1 | |
| SCHEMBL5744902 | 0.81 | GFPT1 (0.47) | EGFRERBB2MAP2K1GFPT1APAF1 | |
| Trifluoroacetic Acid SCHEMBL5744660 | 0.78 | GFPT1 (0.44) | EGFRERBB2GFPT1APAF1NSD2 | |
| SCHEMBL6109223 | 0.77 | GFPT1 (0.43) | EGFRERBB2GFPT1APAF1NSD2 | |
| SCHEMBL5744265 | 0.71 | GFPT1 (0.55) | GFPT1APAF1NSD2CASP3SENP8 | |
| SCHEMBL5758781 | 0.71 | LMNA (0.42) | EGFRERBB2MAP2K1SMN1; SMN2MAPT | |
| SCHEMBL6107565 | 0.70 | GFPT1 (0.52) | GFPT1APAF1NSD2CASP3SENP8 | |
| SCHEMBL5743882 | 0.70 | GFPT1 (0.49) | EGFRERBB2GFPT1APAF1NSD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7067529-B2 | Glutamine fructose-y-phosphate amidotransferase (GFAT) inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2006-06-27 | — | — | US | disclosed |
| EP-1631551-A2 | ISOQUINOLINE DERIVATIVES AND THEIR USE AS GFAT INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-03-08 | — | — | EP | disclosed |
| US-20040259910-A1 | Glutamine fructose-y-phosphate amidotransferase (GFAT) inhibitors | BOLIN DAVID ROBERT (US) | 2004-12-23 | — | — | US | disclosed |
| WO-2004101528-A2 | ISOQUINOLINE DERIVATIVES AND THEIR USE AS GFAT INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259910-A1 | Glutamine fructose-y-phosphate amidotransferase (GFAT) inhibitors | GFPT1, GLS2, GLS | EGFR 2929/4885ERBB2 2423/4885MAP2K1 3715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.